Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Skånberg I[au]:

Omeprazole: pharmacokinetics and metabolism in man. Cederberg C et al. Scand J Gastroenterol Suppl. (1989)

Two-year carcinogenicity studies with the oral direct thrombin inhibitor ximelagatran in the rat and the mouse. Stong DB et al. Int J Toxicol. (2012)

Metabolism of metoprolol in the rat in vitro and in vivo. Arfwidsson A et al. Xenobiotica. (1976)

Search results

Items: 33

1.

Two-year carcinogenicity studies with the oral direct thrombin inhibitor ximelagatran in the rat and the mouse.

Stong DB, Carlsson SC, Bjurström S, Fransson-Steen R, Healing G, Skånberg I.

Int J Toxicol. 2012 Jul-Aug;31(4):348-57. doi: 10.1177/1091581812448881. Epub 2012 Jun 12.

PMID:
22692977
2.

Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.

Lindblom P, Berg AL, Zhang H, Westerberg R, Tugwood J, Lundgren H, Marcusson-Ståhl M, Sjögren N, Blomgren B, Öhman P, Skånberg I, Evans J, Hellmold H.

Toxicol Pathol. 2012;40(1):18-32. doi: 10.1177/0192623311429972. Epub 2011 Nov 30.

PMID:
22131108
3.

Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.

Glinghammar B, Berg AL, Bjurström S, Stockling K, Blomgren B, Westerberg R, Skånberg I, Hellmold H, Andersson U.

Toxicol Pathol. 2011 Feb;39(2):325-36. doi: 10.1177/0192623310394210. Epub 2011 Jan 26.

PMID:
21270424
4.

Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran.

Kenne K, Skanberg I, Glinghammar B, Berson A, Pessayre D, Flinois JP, Beaune P, Edebert I, Pohl CD, Carlsson S, Andersson TB.

Toxicol In Vitro. 2008 Apr;22(3):730-46. doi: 10.1016/j.tiv.2007.11.014. Epub 2007 Dec 3.

PMID:
18191936
5.

Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.

Hellmold H, Zhang H, Andersson U, Blomgren B, Holland T, Berg AL, Elebring M, Sjögren N, Bamberg K, Dahl B, Westerberg R, Dillner B, Tugwood J, Tugwood J, Roberts R, Lundholm E, Camejo G, Skånberg I, Evans J.

Toxicol Sci. 2007 Jul;98(1):63-74. Epub 2007 Apr 27.

PMID:
17468185
6.

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L.

Drug Metab Dispos. 2000 Aug;28(8):966-72.

PMID:
10901708
7.

Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole.

Abelö A, Andersson TB, Bredberg U, Skånberg I, Weidolf L.

Drug Metab Dispos. 2000 Jan;28(1):58-64.

PMID:
10611141
8.

Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.

Andersson T, Olsson R, Regårdh CG, Skånberg I.

Clin Pharmacokinet. 1993 Jan;24(1):71-8.

PMID:
8448974
9.

Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Landahl S, Andersson T, Larsson M, Lernfeldt B, Lundborg P, Regårdh CG, Sixt E, Skånberg I.

Clin Pharmacokinet. 1992 Dec;23(6):469-76.

PMID:
1458764
10.

Omeprazole treatment does not affect the metabolism of caffeine.

Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerström PO, Skånberg I.

Gastroenterology. 1991 Oct;101(4):943-7.

PMID:
1889718
11.

Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

Andersson T, Andrén K, Cederberg C, Lagerström PO, Lundborg P, Skånberg I.

Br J Clin Pharmacol. 1990 May;29(5):557-63.

12.

The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.

Regårdh CG, Andersson T, Lagerström PO, Lundborg P, Skånberg I.

Ther Drug Monit. 1990 Mar;12(2):163-72.

PMID:
2315973
13.

Effect of 20 weeks' ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in the rat.

Wallmark B, Skånberg I, Mattsson H, Andersson K, Sundler F, Håkanson R, Carlsson E.

Digestion. 1990;45(4):181-8.

PMID:
2401392
14.

Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Andersson T, Cederberg C, Regårdh CG, Skånberg I.

Eur J Clin Pharmacol. 1990;39(2):195-7.

PMID:
2253676
15.

Omeprazole: pharmacokinetics and metabolism in man.

Cederberg C, Andersson T, Skånberg I.

Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2. Review.

PMID:
2690330
16.

Biliary excretion of intravenous [14C] omeprazole in humans.

Lind T, Andersson T, Skånberg I, Olbe L.

Clin Pharmacol Ther. 1987 Nov;42(5):504-8.

PMID:
3677539
17.

Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.

Naesdal J, Andersson T, Bodemar G, Larsson R, Regårdh CG, Skånberg I, Walan A.

Clin Pharmacol Ther. 1986 Sep;40(3):344-51.

PMID:
3742939
18.

In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.

Bäärnhielm C, Dahlbäck H, Skånberg I.

Acta Pharmacol Toxicol (Copenh). 1986 Aug;59(2):113-22.

PMID:
3776550
19.

Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.

Regårdh CG, Gabrielsson M, Hoffman KJ, Löfberg I, Skånberg I.

Scand J Gastroenterol Suppl. 1985;108:79-94.

PMID:
3858978
20.

Cytochrome P-450-dependent oxidation of felodipine--a 1,4-dihydropyridine--to the corresponding pyridine.

Bäärnhielm C, Skånberg I, Borg KO.

Xenobiotica. 1984 Sep;14(9):719-26.

PMID:
6516445
21.

Inhibition of gastric acid secretion by omeprazole in the dog and rat.

Larsson H, Carlsson E, Junggren U, Olbe L, Sjöstrand SE, Skånberg I, Sundell G.

Gastroenterology. 1983 Oct;85(4):900-7.

PMID:
6884713
22.
23.

Identification of urinary and biliary metabolites of alprenolol in the rat.

Hoffmann KJ, Arfwidsson A, Borg KO, Skånberg I.

Xenobiotica. 1979 Feb;9(2):93-106.

PMID:
433314
24.

Biotransformation of alprenolol in dog, guinea-pig and rat liver microsomes.

Hoffmann KJ, Skånberg I, Borg KO.

Xenobiotica. 1979 Feb;9(2):79-91.

PMID:
433313
25.

Kinetic studies of dose-dependent metabolism of alprenolol: in vitro and in vivo studies in different species.

Skånberg I, Borg KO, Fellenius E, Hoffmann KJ, von Bahr C, Moldéus P.

Acta Pharmacol Toxicol (Copenh). 1979 Jan;44(1):28-35.

PMID:
760385
26.

Species differences in the metabolism of pamatolol, a cardioselective beta--adrenoceptor antagonist.

Hoffmann KJ, Skånberg I, Borg KO.

Eur J Drug Metab Pharmacokinet. 1979;4(3):163-73.

PMID:
43252
27.

Study of the metabolic pathways of alprenolol in man and the dog using stable isotopes.

Hoffmann KJ, Arfwidsson A, Borg KO, Skånberg I.

Biomed Mass Spectrom. 1978 Nov;5(11):634-40.

PMID:
749958
28.

Metabolism of metoprolol in the rat in vitro and in vivo.

Arfwidsson A, Borg KO, Hoffmann KJ, Skånberg I.

Xenobiotica. 1976 Nov;6(11):691-711.

PMID:
997586
29.

Tissue distribution of metoprolol-(3-h) in the mouse and the rat.

Bodin NO, Borg KO, Johnansson R, Ramsay CH, Skänberg I.

Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):116-24. No abstract available.

PMID:
1079684
30.

The possible role of cytochrome P-450 in the liver "first pass elimination" of a beta-receptor blocking drug.

Grundin R, Moldéus P, Orrenius S, Borg KO, Skånberg I, von Bahr C.

Acta Pharmacol Toxicol (Copenh). 1974 Sep;35(3):242-60. No abstract available.

PMID:
4479306
31.

Metabolism of alprenolol in liver microsomes, perfused liver and conscious rat.

Borg KO, Eklund B, Skånberg I, Wallborg M.

Acta Pharmacol Toxicol (Copenh). 1974 Sep;35(3):169-79. No abstract available.

PMID:
4479244
32.

[Nitration of phenols by means of nitrous acid].

Skanberg I, Nilsson G, Lars J.

Acta Pol Pharm. 1971;28(3):241-6. Polish. No abstract available.

PMID:
5093135
33.

Supplemental Content

Loading ...
Support Center